Nateglinide

Generic Name: Nateglinide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₇NO_₃

CAS Number: 105816-04-4

Unique Ingredient Identifier: 41X3PWK4O2

Background: Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to mea...

Indication: For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Nateglinide/Metformin
Drug: Nateglinide
Drug: Metformin

First Posted Date: 2014-03-17

Last Posted Date: 2014-03-17

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 40

Registration Number: NCT02088918

Locations: 🇰🇷
Chungnam University Hospital, Daejeon, Korea, Republic of

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: ipragliflozin
Drug: nateglinide

First Posted Date: 2011-03-16

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 122

Registration Number: NCT01316107

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nateglinide

First Posted Date: 2010-07-12

Last Posted Date: 2010-07-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 58

Registration Number: NCT01160029

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nateglinide

First Posted Date: 2010-07-09

Last Posted Date: 2010-07-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 68

Registration Number: NCT01159158

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Nateglinide
Drug: Acarbose

First Posted Date: 2009-12-14

Last Posted Date: 2012-10-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT01030952

Locations: 🇨🇳
Shanghai Sixth People's Hospital, 600 Xuanshan Road, Shanghai, China
🇨🇳
Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, China
🇨🇳
Shanghai Tongji Hospital, 389 Xinchun Road, Shanghai, China

Study of the Durability of Glycemic Control With Nateglinide

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Nateglinide
Drug: Glimepiride

First Posted Date: 2009-03-09

Last Posted Date: 2017-05-16

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 88

Registration Number: NCT00858013

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷
Kyung hee University Medical Center, Seoul, Korea, Republic of
🇰🇷
Hanyang University Medical Center, Guri-si, Kyunggi-do, Korea, Republic of

and more 4 locations

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

Phase 4

Completed

Conditions: Diabetes Mellitus
Type 2 Diabetes Mellitus

First Posted Date: 2007-02-21

Last Posted Date: 2008-03-24

Lead Sponsor: Inje University

Target Recruit Count: 85

Registration Number: NCT00437918

Locations: 🇰🇷
Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University, Busan, Korea, Republic of
🇰🇷
Endocrinology and Metabolism, Maryknoll General Hospital, Busan, Korea, Republic of

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Phase 4

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2006-11-22

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT00402909

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

Phase 4

Completed

Conditions: Renal Transplant Recipients
Posttransplant Diabetes Mellitus
Posttransplant Impaired Glucose Tolerance

First Posted Date: 2006-04-27

Last Posted Date: 2006-05-10

Lead Sponsor: University of Oslo School of Pharmacy

Target Recruit Count: 15

Registration Number: NCT00319189

Locations: 🇳🇴
Rikshospitalet, Section of Nephrology, Oslo, Norway

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

Phase 4

Completed

Conditions: Impaired Fasting Glucose
Insulin Resistance

First Posted Date: 2005-11-29

Last Posted Date: 2018-12-03

Lead Sponsor: Atheline Major-Pedersen

Target Recruit Count: 70

Registration Number: NCT00259168

Locations: 🇩🇰
Endothelial laboratory, Cardiology clinic Y-research, H:S Bispebjerg Hospital, Bispebjerg Bakke, Copenhagen, Copenhagen NV, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy